阿德福韦酯联合拉米夫定治疗阿德福韦酯应答不佳的慢性乙型肝炎的临床观察  

The Study of Combined Lamivudine and Adefovir Therapy in HBeAg-positive Chronic Hepatitis B Patients with Poor Response to Adefovir Monotherapy

作　　者：白浪[1] 杨文斌[1] 刘丽[1] 刘聪[1] 唐红[1] 

机构地区：[1]四川大学华西医院感染性疾病中心,成都610041

出　　处：《华西医学》2011年第9期1281-1283,共3页West China Medical Journal

摘　　要：目的观察阿德福韦酯联合拉米夫定治疗阿德福韦酯治疗48周后应答不佳,HBeAg阳性慢性乙型肝炎的疗效和安全性。方法选择2006年1月-2010年12月间阿德福韦酯治疗48周后乙型肝炎病毒DNA>104copies/mL的26例慢性乙型肝炎患者,给与拉米夫定(100 mg,1次/d)联合治疗。观察治疗12周,24周时的应答情况。结果所有纳入26例患者在联合拉米夫定优化治疗24周后,无论是病毒学应答还是血清学应答都获得显著的改善,无一例患者观察到有耐药以及药物不良反应发生。结论联合拉米夫定是对阿德福韦酯应答不佳慢性乙型肝炎患者安全有效的干预策略之一。Objective To observe the eltect anti satety oI aaelowr mp^vux, L ~ v ~ （LAM） in treating HBeAg-positive chronic hepatitis B （CHB） patients with poor response to ADV monotherapy for 48 weeks. Methods Twenty-six FIBeAg-positive CHB patients received initial treatment of ADV from January 2006 to December 2010, and their serum HBV-DNA still maintained over or equal to 1.0 X 104 copies/mL after 48 weeks. These patients received the optimized treatment of ADV （10 rag, one time per day） combined with LAM （100 rag, one time per day）. Patients＇ responses to the treatment at the 12th and 24th week were observed. Results Compared with baseline, ADV plus LAM had an improved response rate of virological response, biochemical response and HBeAg/HBeAb seroconversion. No LAM-resistant or ADV-resistant mutations were detected. In all the 26 patients, no adverse reactions were observed. Conclusion Optimized therapy combining LAM and ADV can be a good choice for patients with hepatitis B who have a poor response to ADV monotherapy,

关 键 词：慢性乙型肝炎 阿德福韦酯 应答不佳 联合治疗 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]